EINSTEIN PE Data Summary & Perspectives on XARELTO (rivaroxaban) in ORS & NVAF Recorded Webcast Update for Analysts and Investors March 26, 2012 1
Webcast Presentation Agenda EINSTEIN PE Clinical Trial Data Summary Dr. Paul Burton, Vice President & Franchise Medical Leader, Cardiovascular & Metabolics, Janssen Research & Development, LLC Perspectives on XARELTO in ORS and NVAF Vanessa Broadhurst, President of Internal Medicine, Janssen Pharmaceuticals, Inc. 2
Safe Harbor Statement This webcast contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. The viewer is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Janssen Research & Development, LLC, Janssen Pharmaceuticals, Inc. and/or Johnson & Johnson. Risks and uncertainties include, but are not limited to, general industry conditions and competition; economic factors, such as interest rate and currency exchange rate fluctuations; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; challenges to patents; impact of business combinations; changes to governmental laws and regulations and domestic and foreign health care reforms; trends toward health care cost containment; increased scrutiny of the health care industry by government agencies; changes in behavior and spending patterns or financial distress of purchasers of health care products and services; manufacturing difficulties or delays; and product efficacy or safety concerns resulting in product recalls or regulatory action. A further list and description of these risks, uncertainties and other factors can be found in Exhibit 99 of Johnson & Johnson s Annual Report on Form 10-K for the fiscal year ended January 1, 2012. Copies of this Form 10-K, as well as subsequent filings, are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. Johnson & Johnson, Janssen Research & Development, LLC and Janssen Pharmaceuticals, Inc. do not undertake to update any forward-looking statements as a result of new information or future events or developments. 3
Rivaroxaban Specific, direct factor Xa inhibitor High oral bioavailability Rapid onset of action Half-life: 7 11 hours Dual mode of elimination: One-third of drug excreted unchanged by the kidneys Two-thirds of drug metabolized by the liver: half excreted renally; half excreted via the hepatobiliary route Phase II dose-finding studies indicated that for VTE treatment a regimen consisting of rivaroxaban 15 mg twice daily for 3 weeks followed by rivaroxaban 20 mg once daily for the subsequent period appeared most optimal 4
Rivaroxaban Developed to Reduce Thrombosis Risk in Diverse Settings TRIAL INDICATION DOSING TRIAL DESIGN STATUS VTE Prevention in patients undergoing total hip or knee replacement 10mg QD for 35 days (hip) or 14 days (knee) >12,500 patients in four studies vs. enoxaparin or enoxaparin / placebo combo Approved Prevention of stroke and systemic embolism in patients with atrial fibrillation 20mg QD (15 mg QD in patients with moderate renal insufficiency) ~14,000 patients vs. warfarin Approved VTE Prevention in hospitalized acute medically ill patients 10mg QD for 35 days ~8,000 patients vs. enoxaparin Study Complete: No filing planned Secondary prevention of cardiovascular events in patients with acute coronary syndrome 5-10 mg QD (in 2 divided doses) ~15,500 patients vs. placebo on background of standard of care snda Filed Action Date: 2Q2012 Treatment and long-term secondary prevention of VTE 15 mg BID day 1-21; 20mg QD for 3, 6 or 12 months ~9,000 patients in three studies vs. enoxaparin + warfarin Study Complete: Anticipated Filing: 2Q2012 5
The Need in Thrombosis Management More than 20 million people in the US are at elevated risk of thrombosis Low awareness of preventable risk More patient-friendly options are needed Better adherence and compliance Improved protection with acceptable safety Faster onset of action Fewer food and drug interactions versus standard of care Elimination of blood monitoring Good tolerability 1. Includes MI, HF, A Fib, THR/TKR, Prior PE/DVT derived from Heart Disease and Stroke Statistics 2009 Update, accessed at http://circ.ahajournals.org/cgi/reprint/circulationaha.108.191261 2. Prevalence of VTE, US Health & Human Services Agency for Healthcare Research and Quality, Talking Points to Attract Administration Support for Venous Thromboembolism Prevention Programs, accessed at http://www.ahrq.gov/qual/vtguide/vtguideapa.htm 6
30-day poststudy treatment period 30-day post-study treatment period EINSTEIN Study Program Confirmed DVT without symptomatic PE Predefined treatment period of 3, 6, or 12 months Day 1 Day 21 N=3,449 Rivaroxaban Rivaroxaban 15 mg bid 20 mg od R Confirmed PE ± symptomatic DVT* N=4,833 Enoxaparin bid for at least 5 days + VKA INR 2.5 (INR range 2 3) Symptomatic DVT or PE completing 6 or 12 months of rivaroxaban or VKA* Day 1 N=1,197 R Predefined treatment period of 6 or 12 months Rivaroxaban 20 mg od Placebo 7
EINSTEIN PE: Study Design Randomized, open-label, event-driven, non-inferiority study Up to 48 hours of heparin/fondaparinux treatment permitted before study entry 88 primary efficacy outcomes needed Non-inferiority margin: 2.0 Objectively confirmed PE ± DVT Predefined treatment period of 3, 6, or 12 months Day 1 Day 21 N=4833 R Rivaroxaban 15 mg bid Rivaroxaban 20 mg od Enoxaparin bid for at least 5 days, plus VKA INR 2.5 range 2.0 3.0) Primary efficacy outcome: first recurrent VTE Principal safety outcome: first clinically relevant major or non major bleeding 30-day post-study treatment period 8
EINSTEIN PE: Primary Efficacy Outcome Analysis Rivaroxaban (N=2419) Enoxaparin/VKA (N=2413) n (%) n (%) First symptomatic recurrent VTE 50 (2.1) 44 (1.8) Recurrent DVT 18 (0.7) 17 (0.7) Recurrent DVT + PE 0 2 (<0.1) Non-fatal PE 22 (0.9) 19 (0.8) Fatal PE/unexplained death where PE can not be ruled out 10 (0.4) 6 (0.2) HR 0.75 1.12 1.68* 0 1.00 2.00 Rivaroxaban superior Rivaroxaban non-inferior Rivaroxaban inferior p=0.57 for superiority (two-sided) P=0.0026 for non-inferiority (one-sided) *Potential relative risk increase <68.4%; absolute risk difference 0.24% ( 0.5 to 1.02) 9
Cumulative event rate (%) EINSTEIN PE: Principal Safety Outcome Major or Non-Major Clinically Relevant Bleeding 15 14 13 12 11 10 9 Rivaroxaban 8 N=2412 7 6 Rivaroxaban Enoxaparin/VKA HR (95% CI) 5 n/n (%) n/n (%) p-value 4 3 249/2412 274/2405 0.90 (0.76 1.07) 2 (10.3) (11.4) p=0.23 1 0 0 30 60 90 120 150 180 210 240 270 300 330 360 Time to event (days) Enoxaparin/VKA N=2405 Number of patients at risk Safety population Rivaroxaban 2412 2183 2133 2024 1953 1913 1211 696 671 632 600 588 313 Enoxaparin/VKA 2405 2184 2115 1990 1923 1887 1092 687 660 620 589 574 251 10
Cumulative event rate (%) EINSTEIN PE: Major Bleeding 3.0 Rivaroxaban n/n (%) Enoxaparin/VKA n/n (%) HR (95% CI) p-value 2.5 2.0 26/2412 (1.1) 52/2405 (2.2) 0.49 (0.31 0.79) p=0.0032 Enoxaparin/VKA N=2405 1.5 1.0 0.5 Rivaroxaban N=2412 0.0 0 30 60 90 120 150 180 210 240 270 300 330 360 Time to event (days) Number of patients at risk Safety population Rivaroxaban 2412 2281 2248 2156 2091 2063 1317 761 735 700 669 659 350 Enoxaparin/VKA 2405 2270 2224 2116 2063 2036 1176 746 719 680 658 642 278 11
EINSTEIN PE: Key Secondary & Other Outcomes Outcome Rivaroxaban Enoxaparin/VKA HR (95% CI) n/n (%) n/n (%) Net clinical benefit* 83/2419 (3.4) 96/2413 (4.0) 0.85 (0.63 1.14) Total mortality 58/2419 (2.4) 50/2413 (2.1) 1.13 (0.77 1.65) On-treatment Cerebrovascular events 12/2412 (0.5) 13/2405 (0.5) ACS 15/2412 (0.6) 21/2405 (0.9) Off-treatment (+ 30 days) Cerebrovascular 2/2206 (<0.1) 1/2197 (<0.1) ACS 3/2206 (0.1) 2/2197 (<0.1) ALT>3 ULN + bilirubin>2 ULN 5/2355 (0.2) 4/2327 (0.2) *Primary efficacy outcome plus major bleeding 12
EINSTEIN PE: Conclusions In patients with acute symptomatic PE with or without DVT, rivaroxaban showed: Non-inferiority to LMWH/VKA for efficacy: HR=1.12 (0.75 1.69); p=0.0026 for non-inferiority margin of 2.0 Similar findings for principal safety outcome: HR=0.90 (0.76 1.07); p=0.23 Superiority for major bleeding: HR=0.49 (0.31 0.79) p=0.0032 Consistent efficacy and safety results irrespective of age, body weight, gender, kidney function and cancer No evidence for liver toxicity For more study details, visit The New England Journal of Medicine online at www.nejm.org, or our press release on www.jnj.com 13
XARELTO (rivaroxaban) Approved US Indications Prevention of deep vein thrombosis (DVT) which may lead to a pulmonary embolism (PE) in people undergoing knee or hip replacement surgery. Reduction in the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation (NVAF). There are limited data on the relative effectiveness of XARELTO and warfarin in reducing the risk of stroke and systemic embolism when warfarin therapy is wellcontrolled. 15
Venous Thromboembolism More than 800,000 people undergo knee or hip replacement surgery in U.S. each year These procedures come with increased blood clot risk If clot breaks off and travels to lungs, a potentially life-threatening PE can form XARELTO helps physicians better protect their patients from these highly preventable surgical complications. 16
Nonvalvular Atrial Fibrillation Most common sustained cardiac rhythm disorder Affects ~2.3 million people in U.S. Causes irregular heart beat Predisposes patient clot formation Increases risk of stroke five-fold XARELTO gives health care professionals and patients the only once-daily option for reducing the risk of stroke without the need for routine blood monitoring 17
NBRx Share NBRx Share in the Oral Anti-Coagulant Market Oral Anti-Coagulant Market NBRx Share 80% 70% 60% 50% 40% XARELTO Share of New to Brand Rxs more than dabigatran 30% 20% 10% 0% 10/07 10/14 10/21 10/28 11/04 11/11 11/18 11/25 12/02 12/09 12/16 12/23 12/30 1/06 1/13 1/20 1/27 2/03 2/10 2/17 2/24 3/02 3/09 XARELTO 3.8% 4.1% 4.8% 5.1% 5.5% 5.8% 6.7% 7.3% 7.8% 8.9% 10.9% 11.0% 8.4% 8.8% 11.3% 12.0% 12.4% 13.6% 13.3% 14.1% 15.0% 15.1% 15.8% Warfarin 73.0% 72.9% 73.2% 72.4% 72.7% 72.2% 71.2% 73.1% 71.7% 71.1% 70.1% 71.7% 73.1% 72.2% 71.2% 71.2% 71.6% 70.4% 70.8% 70.7% 70.4% 70.3% 70.1% Dabigatran 23.2% 23.0% 22.1% 22.5% 21.8% 22.0% 22.1% 19.6% 20.5% 20.0% 19.0% 17.3% 18.4% 19.1% 17.5% 16.8% 16.0% 16.0% 15.9% 15.2% 14.6% 14.5% 14.1% Source: IMS NPA Weekly; data through 3/9/12 18
Novel Oral NRx Share XARELTO and Dabigatran NRx Share of Novel Oral Market (All Strengths) 100.0% 90.0% XARELTO Novel Oral NRx Share Dabigatran Novel Oral NRx Share 80.0% 70.0% 60.0% 86.7% 85.1% 85.8% 82.4% 83.9% 83.4% 80.0% 78.8% 78.4% 76.9% 75.3% 74.2% 74.6% 73.3% 71.3% 71.2% 69.6% 50.0% 40.0% 30.0% 20.0% 28.7% 28.8% 30.4% 13.3% 14.9% 17.6% 20.0% 21.2% 21.6% 23.1% 24.7% 25.8% 25.4% 26.7% 16.1% 16.6% 14.2% 10.0% 0.0% Source: IMS NPA Weekly; data through 3/9/12 19
AF Novel Oral NRx Share XARELTO and Dabigatran NRx Share of NVAF Novel Oral Market XARELTO AF Novel Oral NRx Share Dabigatran AF Novel Oral NRx Share 100.0% 90.0% 99.4% 98.3% 97.5% 96.3% 94.8% 93.6% 95.1% 94.4% 80.0% 92.2% 91.4% 90.1% 88.8% 88.5% 87.6% 86.2% 86.0% 84.8% 70.0% 60.0% 50.0% 40.0% 30.0% 20.0% 10.0% 0.6% 1.7% 2.5% 3.7% 5.2% 6.4% 4.9% 5.6% 7.8% 8.6% 9.9% 11.2% 11.5% 12.4% 13.8% 14.0% 15.2% 0.0% Source: IMS NPA Weekly; data through 3/9/12 20
Very Favorable Formulary Access Majority of plans have XARELTO in Tier 2 or Tier 3 Represents more than 85% of lives covered Medicare Part D: Almost 70% of lives covered in preferred position Commercial plans 35% of lives covered in preferred position Well positioned for even broader coverage by year end 21
Marketplace Dynamics for XARELTO Different marketplace than just 18 months ago Many unstable warfarin patients switched early to dabigatran XARELTO NVAF indication approved more than a year later Competition is focused on indicated unstable patients, new starts or warfarin-stable patients Current market data show: Steady market share growth Increased demand for XARELTO in NVAF and orthopedic surgery indications 22
Robust Pipeline for XARELTO 2 approvals in 2011 (ORS, NVAF) 1 expected decision in 2Q12 (secondary prevention of acute coronary syndrome) FDA priority review status 1 expected filing in 2Q12 (VTE treatment) Strong lifecycle management program Confident about potential of XARELTO in making a meaningful impact in appropriate patients over time 23
Questions? For Investor Relations Inquiries, Contact: Louise Mehrotra at 732-524-6491 Stan Panasewicz at 732-524-2524 For a copy of the EINSTEIN PE data press release, please visit the News section on the Johnson & Johnson website at www.jnj.com/connect/news/product Thank you 24